Abstract: The E157Q and E160Q mutational motif was observed in 35% of INI-naive patients harboring subtype C infections, indicating intra-subtype variations.
Natural polymorphisms of HIV-1 CRF01_AE integrase coding region in ARV-naive individuals in Cambodia, Thailand and Vietnam: an ANRS AC12 working group study.
PMID: 21094281
2011
Infection, genetics and evolution
Abstract: None of the known integrase resistance mutations were observed, except E157Q found in one Cambodian subject (1.1%, CI 95% 0.02-6.3%).
Genetic variation of the HIV-1 integrase region in newly diagnosed anti-retroviral drug-naive patients with HIV/AIDS in Korea.
PMID: 20946407
2011
Clinical microbiology and infection
Abstract: Major mutation sites in the integrase (E92Q, F121Y, G140A/S, Y143C/R, Q148H/R/K and N155H) were not detected, and only a few minor mutation sites (L74M, V151I, E157Q, V165I, I203M, S230N and D232N) were identified in 21 strains (28%).
HIV-1 integrase sequence variability in antiretroviral naive patients and in triple-class experienced patients subsequently treated with raltegravir.
PMID: 20961278
2010
AIDS research and human retroviruses
Abstract: Four ARV-naive (5.3%) and two ARV-treated patients (2.7%) had one of the following minor INI-resistance mutations: L74M, E157Q, G163R, and R263K but there was no association between baseline raltegravir genotype and subsequent response to raltegravir treatment.
Natural polymorphisms of integrase among HIV type 1-infected South African patients.
PMID: 20377427
2010
AIDS research and human retroviruses
Abstract: However, one sample had the T97A mutation, three samples had the E157Q and V165I mutations, and the majority of samples contained the polymorphic mutation V72I.
Abstract: However, the impact of E157Q and other naturally occurring polymorphisms warrants further phenotypic investigation.
The HIV-1 integrase mutations Y143C/R are an alternative pathway for resistance to Raltegravir and impact the enzyme functions.
Method: We followed-up the 50 mutations of resistance present at 32 positions: associated with in vitro or in vivo resistance to HIV-1 integrase inhibitors: H51Y, T66I/A/K, V72I, L74I/A/M, E92Q, T97A, T112I, F121Y, T125K, A128T, E138 K/A/D, G140R/C/H, Y143C/H/R, Q146K/P, S147G, Q148K/R/H, V151I, PMID: 20849300
2010
AIDS research and human retroviruses
Abstract: Substitutions E157Q and E157K, associated with raltegravir resistance, were found in only two CRF06_cpx strains.
Effects of HIV type-1 immune selection on susceptability to integrase inhibitor resistance.
Result: E157Q at the p1 of the known HLA-A*3303-restricted ER9 epitope (ELKKIIGQVR) is strongly associated with HLA-A*3303 in the reference associations dataset and this was also a significant association within the study dataset (P<0.005).
Natural polymorphisms of human immunodeficiency virus type 1 integrase and inherent susceptibilities to a panel of integrase inhibitors.
PMID: 19651917
2009
Antimicrobial agents and chemotherapy
Abstract: E157Q was the only naturally occurring mutation thought to contribute to resistance to elvitegravir, raltegravir, and L-870,810.
Abstract: We identified polymorphisms V72I, L74I, T97A, V151I, M154I/L, E157Q, V165I, V201I, I203M, T206S, and S230N.
Analysis of pol integrase sequences in diverse HIV type 1 strains using a prototype genotyping assay.
PMID: 19327053
2009
AIDS research and human retroviruses
Abstract: Two samples had E92Q (both subtype B) and eight had E157Q (2A, 1C, 1D, 1F, 3 CRF02_AG).
HIV mutation literature information.
PMID: 
2011
Journal of medical virology
Browser Board
Co-occurred Entities
Filtrator
ViMRT